Abstract:Abstract Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). MF is primarily a benign disease often confined to skin. MF, in about 10% of cases, can progress to SS or transform to large-cell histology. SS, the leukemic variant of CTCL, is defined as erythroderma on ≥ 80% of the skin plus ≥1000/μL circulating malignant T-cells. SS is very aggressive with a median overall survival of only 2-5 years. So far, effective treatment options for CTCLs are still very limited and the underlying genetic basis remains incompletely characterized. Here, we performed integrated genomic analyses of 105 patients with de novo or transformed SS, using whole-exome, targeted exon, transcriptome sequencing and SNP array. Frequent somatic alterations were identified in TP53, CARD11, CCR4, PLCG1, TNFRSF1B, CDKN2A, ARID1A, RPS6KA1 and ZEB1. Activating CCR4 and CARD11 mutations were detected in nearly one third of patients. CCR4 is important for T-cell migration into the skin. All CCR4 mutations were either nonsense or frameshift and located at the C-terminus. CARD11 is required for T cell receptor (TCR)-mediated activation of NF-κB signaling. About half of the CARD11 mutations were located in the domain previously reported in diffuse large B cell lymphoma (DLBCL). The remaining mutations were located at a highly conserved new hotspot. As was previously suggested in DLBCL, therapies targeting CARD11 signaling could benefit SS patients. PLCG1 is a key modulator of TCR signaling. In addition to the recently reported S345F hotspot mutation, we identified a new hotspot located in the C-terminal of the protein. The mutation frequency of the new hotspot was significantly higher in patients with prior history of MF, suggesting the possibility that PLCG1 may play a role in transformation of MF to SS. Focal deletion of ZEB1 was observed in over half of the patients. ZEB1 is suggested to be critical for early T-cell development. ZEB1 downregulation contributes to resistance to TGF-β1-mediated growth suppression in adult T-cell leukemia/lymphoma derived cell lines. Loss of ZEB1 may play a similar role in SS pathogenesis. IL32 and IL2RG were strongly upregulated in nearly all patients. IL32 protein expression is correlated with the mRNA expression and the density of Sézary cells in patients’ blood. IL32 accelerates the proliferation of CTCL cell lines through mitogen-activated protein kinase and NF-κB-mediated signaling. IL32 could become a target that is specific to SS patients. Surprisingly, the UVB mutation signature was detected in most of the cases, indicating that the malignant clonal population arose from a cell that spent significant time in the superficial layers of the skin and challenging the view that SS originated from the circulating memory T-cell rather than those resident in the skin. Our results showed profound disruption of key T-cell signaling in SS patients and suggested potential targets for novel therapies. Citation Format: Linghua Wang, Xiao Ni, Kyle R. Covington, Liu Xi, David A. Wheeler, Madeleine Duvic. Molecular pathogenesis of an advanced cutaneous T-cell lymphoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 124.

EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMA

Novel therapeutic approaches for cutaneous T cell lymphomas

New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications

The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma

Cutaneous T cell lymphoma: update on treatment

Current Concepts of the Immunobiology and Immunotherapy of Cutaneous T Cell Lymphoma: Insights Gained through Cross-talk between the Clinic and the Bench

Cell signaling in cutaneous T‐cell lymphoma microenvironment: promising targets for molecular‐specific treatment

CCR4 in cutaneous T‐cell lymphoma: Therapeutic targeting of a pathogenic driver

Epigenetics Of Cutaneous T-Cell Lymphoma: Biomarkers And Therapeutic Potentials

Modulation of the skin microbiome in cutaneous T-cell lymphoma delays tumour growth and increases survival in the murine EL4 model

Emerging therapies in mantle cell lymphoma

Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma

Cutaneous T Cell Lymphoma Atlas Reveals Malignant Th2 Cells Supported by a B Cell-Rich Microenvironment

From Molecules to Microbes: Tracing Cutaneous T-Cell Lymphoma Pathogenesis through Malignant Inflammation

The Role of Cytokines in Cutaneous T Cell Lymphoma: A Focus on the State of the Art and Possible Therapeutic Targets

Advances in the pharmacological management of cutaneous T-cell lymphoma

MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma

Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma

Non-coding RNAs in the spotlight of the pathogenesis, diagnosis, and therapy of cutaneous T cell lymphoma

Abstract 124: Molecular Pathogenesis of an Advanced Cutaneous T-cell Lymphoma

Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma